Four Decades for Justice
On December 7, 2019, Janssen Biotech, Inc. (“Janssen Biotech”), a Janssen Pharmaceutical Company of Johnson & Johnson, announced that it entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody in Phase 2 development for the treatment of atopic dermatitis and hidradenitis suppurativa, which are chronic, immune-mediated skin diseases. Cravath is representing Janssen Biotech in connection with the transaction.
The Cravath team is led by partner Robert I. Townsend III and includes associates Matthew L. Ploszek, Jin-Kyu Baek and Carly J. Goeman on M&A matters; partner J. Leonard Teti II and associate Andrew T. Davis on tax matters; partner David J. Kappos and associates F. Adam Abulawi and Somi A. Umolu on intellectual property matters; partner Jonathan J. Katz and associates Matthew J. Bobby and Sally Ye on executive compensation and benefits matters; partner Matthew Morreale on environmental matters; and practice area attorney Brian M. Budnick on real estate matters.
Deals & Cases
November 01, 2022
On November 1, 2022, Johnson & Johnson and Abiomed, a leader in breakthrough heart, lung and kidney support technologies, announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right (“CVR”) entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved. Cravath is representing Johnson & Johnson in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.